My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 164

    1.

    The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

    Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA.

    Ann Intern Med. 1987 Sep;107(3):293-300.PMID: 3497595 [PubMed - indexed for MEDLINE]Related articles

    2.

    Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

    Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al.

    Ann Intern Med. 1988 Apr;108(4):518-23.PMID: 3258138 [PubMed - indexed for MEDLINE]Related articles

    3.

    A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.

    N Engl J Med. 1987 Apr 9;316(15):889-97.PMID: 3493432 [PubMed - indexed for MEDLINE]Related articles

    4.

    Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

    Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, et al.

    Cancer Res. 1989 Dec 1;49(23):6832-9.PMID: 2819723 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al.

    J Natl Cancer Inst. 1993 Apr 21;85(8):622-32. Erratum in: J Natl Cancer Inst 1993 Jul 7;85(13):1091. PMID: 8468720 [PubMed - indexed for MEDLINE]Related articles

    6.

    Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.

    Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y.

    Hepatology. 1989 Sep;10(3):349-53.PMID: 2474481 [PubMed - indexed for MEDLINE]Related articles

    7.

    Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

    Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA.

    Cancer Immunol Immunother. 1998 Aug;46(6):318-26.PMID: 9756416 [PubMed - indexed for MEDLINE]Related articles

    8.

    Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.

    N Engl J Med. 1985 Dec 5;313(23):1485-92.PMID: 3903508 [PubMed - indexed for MEDLINE]Related articles

    9.

    The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.

    Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, Thomas JX Jr, Fisher SG, Fisher RI.

    Ann Intern Med. 1988 Dec 15;109(12):953-8.PMID: 3264128 [PubMed - indexed for MEDLINE]Related articles

    10.

    A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.

    Eberlein TJ, Schoof DD, Jung SE, Davidson D, Gramolini B, McGrath K, Massaro A, Wilson RE.

    Arch Intern Med. 1988 Dec;148(12):2571-6.PMID: 3264142 [PubMed - indexed for MEDLINE]Related articles

    11.

    Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

    Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H.

    Cancer Res. 1987 Aug 1;47(15):4208-12.PMID: 3496958 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.

    Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM.

    Ann Oncol. 1994 May;5(5):447-52.PMID: 7521206 [PubMed - indexed for MEDLINE]Related articles

    13.

    Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.

    Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S.

    J Immunother. 1997 Jan;20(1):79-87.PMID: 9101417 [PubMed - indexed for MEDLINE]Related articles

    14.

    Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

    Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM.

    N Engl J Med. 1988 Jun 16;318(24):1557-63.PMID: 3259674 [PubMed - indexed for MEDLINE]Related articles

    15.

    Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

    Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J.

    Cancer. 1995 Sep 1;76(5):840-52.PMID: 8625188 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

    Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA.

    Ann Intern Med. 1987 Jun;106(6):817-22.PMID: 3495213 [PubMed - indexed for MEDLINE]Related articles

    17.

    [Alpha-interferon and mental disorders]

    Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D.

    Encephale. 2001 Jul-Aug;27(4):308-17. Review. French. PMID: 11686052 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells]

    Jost LM, Gmür J, Oelz O, Sauter C, Stahel RA.

    Schweiz Med Wochenschr. 1988 Feb 4;119(5):137-43. German. PMID: 3266369 [PubMed - indexed for MEDLINE]Related articles

    19.

    Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

    Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA.

    Blood. 1987 Jun;69(6):1654-60.PMID: 3495302 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Dermatologic changes associated with interleukin 2 administration.

    Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI.

    JAMA. 1987 Sep 25;258(12):1624-9.PMID: 3306005 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity